Enveric Biosciences

Enveric Biosciences, headquartered in Naples, Florida, is a biotechnology company specializing in the research and development of innovative treatments for mental health conditions. With six employees, Enveric focuses on developing novel neuroplastogenic small-molecule therapeutics, aiming to address anxiety, depression, and addiction disorders. The company's core technology, The Psybrary™, allows for the creation of a diverse portfolio of intellectual property, encompassing new chemical entities specifically tailored for various mental health indications. Their flagship program, the EVM201 Series, focuses on synthetic prodrugs of psilocin, targeting anxiety disorders. Their second program, EVM301 Series, aims to offer a novel approach to treating challenging mental health disorders, promoting neuroplasticity without causing hallucinations. Enveric Biosciences distinguishes itself through its innovative discovery and development platform, The Psybrary™, which enables the creation of targeted therapies. The company's commitment to developing innovative treatments with fewer side effects, particularly the EVM301 Series' focus on neuroplasticity without hallucinations, sets it apart in the field. Interested parties can learn more about Enveric Biosciences and their groundbreaking research at enveric.com.